Selected article for: "BIS group and study secondary outcome"
Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma
  • Document date: 2018_8_30
    • ID: uzge50xu_17
    Snippet: Another secondary outcome of this study was changes in rescue medication usage with treatment. Comparisons were done in 3 ways: 1) within each group (BIS and MONT), usage at run-in (−2 weeks) was compared to usage at the end of the treatment period (12 weeks); 2) each subject in each group was analyzed over the study period (−2 to 12 weeks) to determine any change in usage; 3) usage in BIS group was compared to usage in MONT group at each tim.....
    Document: Another secondary outcome of this study was changes in rescue medication usage with treatment. Comparisons were done in 3 ways: 1) within each group (BIS and MONT), usage at run-in (−2 weeks) was compared to usage at the end of the treatment period (12 weeks); 2) each subject in each group was analyzed over the study period (−2 to 12 weeks) to determine any change in usage; 3) usage in BIS group was compared to usage in MONT group at each time point (−2, 0, 4, 8 and 12 weeks). For each endpoint, stratified analysis was performed based on the virus type detected.

    Search related documents:
    Co phrase search for related documents
    • study secondary outcome and time point MONT group usage: 1
    • study secondary outcome and treatment period: 1, 2
    • study secondary outcome and treatment rescue medication usage change: 1
    • study secondary outcome and usage change: 1
    • time point and treatment period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • time point and treatment rescue medication usage change: 1
    • time point and usage change: 1
    • time point and usage change determine: 1
    • time point and virus type: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • time point MONT group usage and treatment period: 1
    • time point MONT group usage and treatment rescue medication usage change: 1
    • time point MONT group usage and usage change: 1
    • time point MONT group usage and usage change determine: 1
    • treatment period and usage change: 1
    • treatment period and usage change determine: 1
    • treatment period and virus type: 1, 2, 3
    • treatment rescue medication usage change and usage change: 1
    • treatment rescue medication usage change and usage change determine: 1
    • usage change and virus type: 1